NASDAQ:CNTB Connect Biopharma Q3 2025 Earnings Report $2.31 +0.12 (+5.48%) Closing price 05/20/2026 04:00 PM EasternExtended Trading$2.37 +0.06 (+2.55%) As of 08:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Connect Biopharma EPS ResultsActual EPS-$0.31Consensus EPS -$0.24Beat/MissMissed by -$0.07One Year Ago EPSN/AConnect Biopharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConnect Biopharma Announcement DetailsQuarterQ3 2025Date11/12/2025TimeBefore Market OpensConference Call DateWednesday, November 12, 2025Conference Call Time9:00AM ETUpcoming EarningsConnect Biopharma's Q2 2026 earnings is estimated for Thursday, May 21, 2026, based on past reporting schedulesConference Call ResourcesPress Release (6-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(6-K)Quarterly Report(10-Q) Connect Biopharma Earnings HeadlinesConnect Biopharma (NASDAQ:CNTB) Rating Lowered to Sell at Wall Street ZenMay 16, 2026 | americanbankingnews.comCompanies Like Connect Biopharma Holdings (NASDAQ:CNTB) Could Be Quite RiskyMay 15, 2026 | finance.yahoo.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.May 21 at 1:00 AM | Banyan Hill Publishing (Ad)Connect Biopharma Holdings Ltd.May 14, 2026 | cnn.comConnect Biopharma (CNTB) Expected to Announce Quarterly Earnings on ThursdayMay 14, 2026 | americanbankingnews.comConnect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor ConferenceMay 12, 2026 | globenewswire.comSee More Connect Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Connect Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Connect Biopharma and other key companies, straight to your email. Email Address About Connect BiopharmaConnect Biopharma (NASDAQ:CNTB) Holdings Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody therapies for immune-mediated disorders. Headquartered in Singapore with a research and commercial presence in the United States, the company applies proprietary technology platforms to target novel pathways in inflammatory and autoimmune diseases. The company’s lead product candidate, CBP-201, is a fully human monoclonal antibody that antagonizes the interleukin-31 receptor, a key mediator of chronic pruritus in conditions such as atopic dermatitis and prurigo nodularis. A second clinical-stage program, CBP-701, selectively inhibits signaling through tumor necrosis factor receptor 1 (TNFR1), a strategy designed to preserve beneficial TNFR2 activity while reducing the risk of systemic immunosuppression. Together, these candidates reflect Connect Biopharma’s commitment to developing differentiated therapies with potentially improved safety and efficacy profiles. Since its founding in 2015, Connect Biopharma has advanced its pipeline through early-phase clinical trials and established strategic partnerships to support long-term development goals. The company completed its initial public offering on the Nasdaq Global Market under the ticker CNTB in 2021, raising capital to fund ongoing studies and expand its research capabilities. Its clinical programs are being evaluated across multiple geographies, including North America and the Asia-Pacific region. Connect Biopharma is led by an executive team and board of directors with extensive experience in biotechnology, pharmaceutical development and commercialization. Leveraging a blend of scientific rigor and clinical expertise, the management group aims to bring novel immunology treatments to patients with high unmet medical need.View Connect Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Freight Boom: The Hormuz Blockade PaydayTJX Companies Fires on All Cylinders With 9% Revenue GrowthAnalog Devices Provides Much-Needed Pullback: How Low Can It Go?USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal LoomsFrom Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 OutlookThe Palantir Paradox—Record Numbers and a Stock That Won't CooperateMirum Pharma: A Rare Disease Growth Story to Watch Upcoming Earnings AutoZone (5/26/2026)Marvell Technology (5/27/2026)PDD (5/27/2026)Synopsys (5/27/2026)Bank Of Montreal (5/27/2026)Bank of Nova Scotia (5/27/2026)Salesforce (5/27/2026)Snowflake (5/27/2026)Autodesk (5/28/2026)Costco Wholesale (5/28/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
